Last reviewed · How we verify
CT-P6
CT-P6 is a monoclonal antibody that binds to and inhibits tumor necrosis factor alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases.
CT-P6 is a monoclonal antibody that binds to and inhibits tumor necrosis factor alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | CT-P6 |
|---|---|
| Sponsor | Celltrion |
| Drug class | TNF-α inhibitor (monoclonal antibody); infliximab biosimilar |
| Target | TNF-α (tumor necrosis factor alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
CT-P6 is a biosimilar of infliximab, a chimeric monoclonal antibody that targets TNF-α, a key pro-inflammatory cytokine. By neutralizing TNF-α, it suppresses the inflammatory cascade involved in autoimmune conditions. This mechanism allows reduction of systemic inflammation and immune-mediated tissue damage in diseases like rheumatoid arthritis and inflammatory bowel disease.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
Common side effects
- Infections (including serious infections)
- Infusion reactions
- Headache
- Nausea
- Tuberculosis reactivation risk
Key clinical trials
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (PHASE2)
- Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer (PHASE3)
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial (PHASE2)
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers (PHASE2)
- Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P6 CI brief — competitive landscape report
- CT-P6 updates RSS · CI watch RSS
- Celltrion portfolio CI